Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer

Fabian Stögbauer(Technical University of Munich), Jan Budczies(German Cancer Research Center), Maren Lauterbach(TUM Klinikum), Wilko Weichert(Deutsches Konsortium für Translationale Krebsforschung), Moritz Jesinghaus(Philipps University of Marburg), Susanne Beck, Iordanis Ourailidis(Heidelberg University), Albrecht Stenzinger(Heidelberg University), Anna Maria Stefanie Buchberger(TUM Klinikum), Jochen Heß(Heidelberg University), Peter Schirmacher(Heidelberg University), Melanie Boxberg(Starnberg Hospital), Christopher Poremba(Heinrich Heine University Düsseldorf), Barbara Wollenberg(Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde)
British Journal of Cancer
April 12, 2023
10.1038/s41416-023-02240-y
Cited by 30

Related Papers

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
|Nature|2018|455
Fungi and inflammatory bowel diseases: Alterations of composition and diversity
|Scandinavian Journal of Gastroenterology|2008|432